It was a busy and exciting American College of Cardiology 2013 conference. It’s great to see clinical experience validated with science presented in conjunction with the ACC.13 prevention track sessions.
It is encouraging that the evidence continues to build for emerging lipid risk factors in major population segments of the U.S. population. This includes technical inadequacies of Friedewald LDL calculation, which has been the mainstay of the basic lipid panel for more than 40 years. One thing is clear: there is a need for direct LDL measurement that also provides accurate non-HDL component measures and lipid subclasses for cardiovascular risk identification and prevention.
Highlights of ACC.13 presentations included:
- Two excellent ACC.13 posters presentations by Peter P. Toth, M.D., identified TG-rich remnant lipoproteins and HDL subclasses as significant, independent risk factors in heart disease, and highlighted the need for more research in this important area of preventive cardiology.
- In a cohort of the Intermountain Heart Study, Heidi T. May, Ph.D., of the Intermountain Medical Center Heart Institute provided further insight into LDL subclasses (LDL3 and LDL4) and apolipoprotein B as significant predictors of heart attack, death, and repeat revascularization (MACE).
- Researcher Mohamed B. Elshazly, M.D., and his team discovered significant disagreement (discordance) between key lipid calculations in the basic lipid panel and the direct measures in the VAP Lipid Panel, concluding that more research into better lipid risk assessment and the exploration of multiple lipid parameters in treatment decisions must be undertaken.
- Wrapping up the science involving the VAP Lipid Panel was a very well-researched oral presentation Sunday morning in front of a large audience on the impact of TG-rich remnant lipoproteins presented by Dr. Arif Khokhar of Northwest London Hospitals in the United Kingdom.